Log in

Relevant bibliographies by topics / Immune / Journal articles

Journal articles on the topic 'Immune'

To see the other types of publications on this topic, follow the link: Immune.

Author: Grafiati

Published: 4 June 2021

Last updated: 18 May 2024

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Immune.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Chattopadhyay, Pratip K., Woodrow E. Lomas, Guo-Jian Gao, Na Li, and Suraj Saksena. "Immune monitoring for immuno-oncology applications." Journal of Immunology 204, no. 1_Supplement (May 1, 2020): 159.29. http://dx.doi.org/10.4049/jimmunol.204.supp.159.29.

Full text

Abstract:

Abstract The immunotherapy revolution has spurred the development of many new drugs and drug regimens for patient treatment. A key challenge is to identify the factors that drive patient toxicities and responses to treatment, with a particularly acute need for predictive biomarkers that can discriminate patients destined to respond and fail treatment. Technologies to interrogate immune cells are now readily available, but important gaps remain in their application, which limit the full realization of the promise of precision oncology. High parameter flow cytometry is a gold-standard but is limited by difficulty of panel design and lack of standardization. We present Color Wheel, a panel design tool, which builds optimized antibody panels based on the user’s instrument. These optimized panels have been manufactured in a dried, ready to use format to drive workflow and assay standardization. Initial results demonstrate excellent concordance between the dried and liquid versions of the high parameter multicolor panel(s). Molecular cytometry represents an exciting new approach to high dimensional immune analysis because it can measure at least 102 proteins and 400 mRNA targets simultaneously per cell. An important application gap for this technology is lack of data indicating the sequencing depth needed for adequate resolution. Here, we present results from a molecular cytometry experiment sequenced deeply, and then bioinformatically sub-sampled at different levels to identify the minimum level of sequencing needed for clear identification of cells, which can serve as a reference guide for users to save time and cost in their experiments. We also present preliminary data generated using dried version of molecular cytometry panel(s).

APA, Harvard, Vancouver, ISO, and other styles

2

Kannan, Rajni, Kathleen Madden, and Stephanie Andrews. "Primer on Immuno-Oncology and Immune Response." Clinical Journal of Oncology Nursing 18, no. 3 (May 27, 2014): 311–17. http://dx.doi.org/10.1188/14.cjon.311-317.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Holmström, Morten Orebo, Sabrina Cordua, Vibe Skov, Lasse Kjær, Niels Pallisgaard, Christina Ellervik, Hans Carl Hasselbalch, and Mads Hald Andersen. "Evidence of immune elimination, immuno-editing and immune escape in patients with hematological cancer." Cancer Immunology, Immunotherapy 69, no. 2 (January 8, 2020): 315–24. http://dx.doi.org/10.1007/s00262-019-02473-y.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

HK, Singhal. "Suvarnaprashan: An Ayurvedic Immune Booster." Journal of Natural & Ayurvedic Medicine 5, no. 3 (July 13, 2021): 1–4. http://dx.doi.org/10.23880/jonam-16000325.

Full text

Abstract:

The word 'Suvarnaprashan', a logical offshoot of Ayurveda, is made with combination of two words 'Suvarna' and 'Prashan'. The term Suvarna is a common word which refers to the Gold noble metal. Prashan refers to Pra+Ashan which means specially the act of eating or drinking or in taking. Suvarnaprashan has been practiced since a long back to make Vyadhikshamatva i.e. Immunity stronger to prevent infectious diseases as well as maintenance of good physical and mental growth and development of a child. According to WHO, Health is a state of complete physical, mental and social wellbeing and not merely the absence of disease or infirmity. In the wider context, health is a state of total absence of illnesses, diseases, syndromes, infections, abnormal behavior, accidents etc. Vyadhikshamatva i.e. immunity or resistance is the power that protects the body from diseases. It depends on Ojas, Bala, Prakrita Kapha and Balavardhaka Bhava. There has been a significant deterioration in the quality of human health status from generation to generation resulting in decline of immunity. Samskara, Lehana and Rasayana medicines, Suvarnaprashan etc. are recommended in Ayurveda for children for the promotion of health and longevity of life span. According to ancient Ayurved Acharyas like Acharya Kashyap, Sushrut and Vagbhat, Suvarnaprashan strengthens immunity and simultaneously improves digestive functions, intellectual capabilities, activeness and vital power of the body, hence keeps a child healthy. Suvarnaprashan contributes in proper achievement of milestones significantly during growth and development process also.

APA, Harvard, Vancouver, ISO, and other styles

5

Dahal, Tshetiz, and Subarna Rizal. "INNATE IMMUNE CELLSIN IMMUNE TOLERANCE AFTER LIVER TRANSPLANTATION." International Journal of Advanced Research 10, no. 04 (April 30, 2022): 506–15. http://dx.doi.org/10.21474/ijar01/14575.

Full text

Abstract:

Currently, liver transplantation is the most effective treatment for end-stage liver disease. Immuno-suppressive agents are required to be taken after the operations, which have significantly reduced rejection rates and improved the short-term (<1 year) survival rates. However, post-transplant complications related to the immuno-suppressive therapy have led to the development of new protocols aimed at protecting renal function and preventing de novo cancer and dysmetabolic syndrome. Donor specific immune tolerance, which means the mature immune systems of recipients will not attack the grafts under the conditions without any immunosuppression therapies, is considered the optimal state after liver transplantation. There have been studies that have shown that some patients can reach this immune tolerance state after liver transplantation. The intrahepatic immune system is quite different from that in other solid organs, especially the innate immune system. It contains a variety of liver specific cells, such as liver-derived dendritic cells, Kupffer cells, liver sinusoidal endothelial cells, liver-derived natural killer (NK) cells, natural killer T (NKT) cells, and so on. Depending on their specific structures and functions, these intrahepatic innate immune cells play important roles in the development of intrahepatic immune tolerance. In this article, in order to have a deeper understanding of the tolerogenic functions of liver, we summarized the molecular mechanisms of immune tolerance induced by intrahepatic innate immune cells after liver transplantation.

APA, Harvard, Vancouver, ISO, and other styles

6

Shastri, Nilabh, Chansu Park, and Jian Guan. "Immune surveillance of immune surveillance." Molecular Immunology 150 (October 2022): 2. http://dx.doi.org/10.1016/j.molimm.2022.05.018.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Warsof, Steven L., Kypros H. Nicolaides, and Charles Rodeck. "Immune and Non-immune Hydrops." Clinical Obstetrics and Gynecology 29, no. 3 (September 1986): 533–42. http://dx.doi.org/10.1097/00003081-198609000-00009.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Yazdanbakhsh, Karina, Hui Zhong, and Weili Bao. "Immune Dysregulation in Immune Thrombocytopenia." Seminars in Hematology 50 (January 2013): S63—S67. http://dx.doi.org/10.1053/j.seminhematol.2013.03.011.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Davies, Graham E. "Immune mechanisms and immune deficiency." Current Opinion in Pediatrics 2, no. 1 (February 1990): 106–9. http://dx.doi.org/10.1097/00008480-199002000-00020.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Skhiri, S., J. Anoun, B. H. Imen, A. Mzabi, F. Ben Fredj, M. Karmani, B. Achour, A. Rezgui, and L. Chadia. "Anémie hémolytique auto-immune et maladies auto-immunes." La Revue de Médecine Interne 41 (December 2020): A91. http://dx.doi.org/10.1016/j.revmed.2020.10.146.

Full text

APA, Harvard, Vancouver, ISO, and other styles

11

Ouerghi, H., Z. Ben Ali, N. Maamouri, N. Belkahla, S. Chouaib, F. Ben Hriz, H. Chaabouni, and N. Ben Mami. "Maladies auto-immunes associées à l’hépatite auto-immune." La Revue de Médecine Interne 31 (June 2010): S165. http://dx.doi.org/10.1016/j.revmed.2010.03.272.

Full text

APA, Harvard, Vancouver, ISO, and other styles

12

Guermazi, W., N. Maamouri, N. Belkahla, N. Naija, B. Mohsni, S. Chouaib, and N. Ben Mami. "Maladies auto-immunes associées à l’hépatite auto-immune." La Revue de Médecine Interne 33 (June 2012): S169—S170. http://dx.doi.org/10.1016/j.revmed.2012.03.291.

Full text

APA, Harvard, Vancouver, ISO, and other styles

13

Azar, Sami. "Hypophysitis due to Immune Checkpoint Inhibitors." Endocrinology and Disorders 5, no. 1 (March 5, 2021): 01–07. http://dx.doi.org/10.31579/2640-1045/055.

Full text

Abstract:

Immune checkpoint inhibitors are antineoplastic drugs associated with adverse events that result from unleashing the immune system against self-antigens while attacking neoplastic cells. Endocrinopathies are among the most common associated adverse events and hypophysitis is a frequent endocrine side effect of this treatment. We conducted a systematic search of the literature in 2 databases: PubMed and Medline. Articles that reported endocrine adverse events of immune checkpoint inhibitors were reviewed. Hypophysitis is most commonly seen with cytotoxic T-lymphocytes associated protein 4 (CTLA-4) inhibitors and can result in different anterior pituitary hormones deficiencies. Monitoring for this complication is of particular interest due to the life-threatening nature of secondary adrenal insufficiency and thyroid dysfunction if not promptly recognized and treated. Hypophysitis is the most common endocrinopathy seen and is usually treated by adequate hormonal replacement. The use of high dose corticosteroids has not been established as a treatment of this endocrine toxicity. Hormonal screening should be a part of baseline laboratory testing of all patients undergoing treatment with immune checkpoint inhibitors.

APA, Harvard, Vancouver, ISO, and other styles

14

Borst, Katharina, Anaelle Aurelie Dumas, and Marco Prinz. "Microglia: Immune and non-immune functions." Immunity 54, no. 10 (October 2021): 2194–208. http://dx.doi.org/10.1016/j.immuni.2021.09.014.

Full text

APA, Harvard, Vancouver, ISO, and other styles

15

Komatsu, Norio. "1. Immune Thrombocytopenic Purpura (Immune Thrombocytopenia)." Nihon Naika Gakkai Zasshi 103, no. 7 (2014): 1593–98. http://dx.doi.org/10.2169/naika.103.1593.

Full text

APA, Harvard, Vancouver, ISO, and other styles

16

Joob, Beuy, and Viroj Wiwanitkit. "Neurocysticercosis, immune status and immune response." Arquivos de Neuro-Psiquiatria 70, no. 9 (September 2012): 750. http://dx.doi.org/10.1590/s0004-282x2012000900023.

Full text

APA, Harvard, Vancouver, ISO, and other styles

17

&NA;. "Ganciclovir/cytomegalovirus immune globulin/immune globulin." Reactions Weekly &NA;, no. 1332 (December 2010): 21. http://dx.doi.org/10.2165/00128415-201013320-00069.

Full text

APA, Harvard, Vancouver, ISO, and other styles

18

Kumar, Himanshu. "Balancing immune tolerance and immune responses." International Reviews of Immunology 39, no. 2 (February 20, 2020): 37–38. http://dx.doi.org/10.1080/08830185.2020.1723961.

Full text

APA, Harvard, Vancouver, ISO, and other styles

19

Yazdanbakhsh, Karina. "Imbalanced immune homeostasis in immune thrombocytopenia." Seminars in Hematology 53 (April 2016): S16—S19. http://dx.doi.org/10.1053/j.seminhematol.2016.04.006.

Full text

APA, Harvard, Vancouver, ISO, and other styles

20

Kurosawa, Shin, and Masato Kato. "Anesthetics, immune cells, and immune responses." Journal of Anesthesia 22, no. 3 (August 2008): 263–77. http://dx.doi.org/10.1007/s00540-008-0626-2.

Full text

APA, Harvard, Vancouver, ISO, and other styles

21

Moss, William J., Martin O. Ota, and Diane E. Griffin. "Measles: immune suppression and immune responses." International Journal of Biochemistry & Cell Biology 36, no. 8 (August 2004): 1380–85. http://dx.doi.org/10.1016/j.biocel.2004.01.019.

Full text

APA, Harvard, Vancouver, ISO, and other styles

22

Ben Slama, A., L. Golli, A. Jmaa, H. Turki, and S. Ajmi. "Les maladies auto-immunes associées à l’hépatite auto-immune." La Revue de Médecine Interne 30 (June 2009): S99—S100. http://dx.doi.org/10.1016/j.revmed.2009.03.198.

Full text

APA, Harvard, Vancouver, ISO, and other styles

23

Haig, David M., Jackie Thomson, Colin McInnes, Catherine McCaughan, Wendy Imlach, Andrew Mercer, and Stephen Fleming. "Orf virus immuno-modulation and the host immune response." Veterinary Immunology and Immunopathology 87, no. 3-4 (September 2002): 395–99. http://dx.doi.org/10.1016/s0165-2427(02)00087-9.

Full text

APA, Harvard, Vancouver, ISO, and other styles

24

Anoun, J., B. Achour, A. Rezgui, H. Regaieg, Y. Ben Youssef, and A. Khelif. "Association anémie hémolytique auto-immune et maladies auto-immunes." La Revue de Médecine Interne 35 (June 2014): A89—A90. http://dx.doi.org/10.1016/j.revmed.2014.03.122.

Full text

APA, Harvard, Vancouver, ISO, and other styles

25

Ibrahim, A. M., Y. Wang, and N. R. Lemoine. "Immune-checkpoint blockade: the springboard for immuno-combination therapy." Gene Therapy 22, no. 11 (November 2015): 849–50. http://dx.doi.org/10.1038/gt.2015.98.

Full text

APA, Harvard, Vancouver, ISO, and other styles

26

R, Verma. "Understanding Emotional Roots of Human Immune System." Virology & Immunology Journal 5, no. 2 (April 1, 2021): 1–5. http://dx.doi.org/10.23880/vij-16000277.

Full text

Abstract:

Decades of research has provided evidence that various psychological factors have a huge impact over the immune system which systematically stimulate it to give positive or negative responses and can time to time show several levels of modulations. These modulations or responses may enhance or may adversely affect the immune function of an individual. This review article focuses on affects and its roots to the human immune system, supported by various studies conducted in different times. The paper also discusses all the possible pathways by which emotion can connect with the immune function and vice-versa, how stress can affect the immune response as well as how the elements of psychological factors can modulate the immune function of an individual

APA, Harvard, Vancouver, ISO, and other styles

27

Oberhardt, Valerie, Maike Hofmann, Robert Thimme, and Christoph Neumann-Haefelin. "Adaptive Immune Responses, Immune Escape and Immune-Mediated Pathogenesis during HDV Infection." Viruses 14, no. 2 (January 20, 2022): 198. http://dx.doi.org/10.3390/v14020198.

Full text

Abstract:

The hepatitis delta virus (HDV) is the smallest known human virus, yet it causes great harm to patients co-infected with hepatitis B virus (HBV). As a satellite virus of HBV, HDV requires the surface antigen of HBV (HBsAg) for sufficient viral packaging and spread. The special circumstance of co-infection, albeit only one partner depends on the other, raises many virological, immunological, and pathophysiological questions. In the last years, breakthroughs were made in understanding the adaptive immune response, in particular, virus-specific CD4+ and CD8+ T cells, in self-limited versus persistent HBV/HDV co-infection. Indeed, the mechanisms of CD8+ T cell failure in persistent HBV/HDV co-infection include viral escape and T cell exhaustion, and mimic those in other persistent human viral infections, such as hepatitis C virus (HCV), human immunodeficiency virus (HIV), and HBV mono-infection. However, compared to these larger viruses, the small HDV has perfectly adapted to evade recognition by CD8+ T cells restricted by common human leukocyte antigen (HLA) class I alleles. Furthermore, accelerated progression towards liver cirrhosis in persistent HBV/HDV co-infection was attributed to an increased immune-mediated pathology, either caused by innate pathways initiated by the interferon (IFN) system or triggered by misguided and dysfunctional T cells. These new insights into HDV-specific adaptive immunity will be discussed in this review and put into context with known well-described aspects in HBV, HCV, and HIV infections.

APA, Harvard, Vancouver, ISO, and other styles

28

Jackson-Spence, Francesca, Agne Jovaisaite, Michael Grant, Wing-Kin Liu, Thomas Butters, Thomas Powles, and Bernadett Szabados. "Outcomes after first-line therapy for immune/immune or immune/VEGF combinations." Journal of Clinical Oncology 38, no. 6_suppl (February 20, 2020): 706. http://dx.doi.org/10.1200/jco.2020.38.6_suppl.706.

Full text

Abstract:

706 Background: The introduction of first line immune combination or immune/VEGF therapy in metastatic renal cancer has changed treatment landscape. Here we compare outcomes of these combinations with patients treated with first line sunitinib. The focus is on the impact of subsequent treatments. Methods: This retrospective analysis was performed at Barts Cancer Institute for consecutive patients from April 2015 when front line immune therapy was first used at our institution. Only patients enrolled on reported prospective trials were included to avoid selection bias. Patients were treated with VEGF targeted therapy (n=35) (group V), PD-1 + CTLA4 (n=15) (group I/I) or a combination of PD-L1 + VEGF TKI inhibitor (n=29) (group I/V). The primary analysis focused on the proportion of patients who received second line therapy and their outcome. Results: 79 patients received first line therapy for clear cell RCC. IMDC good, intermediate and poor risk occurred in 27.8%, 60.8% and 11.4% respectively. Front line response rates for V, I/I and I/V groups were 34.3%, 46.7% and 65.5% and PFS in V, I/I and I/V groups were 11mo (95%CI 6-16), 18mo (95% CI 0-41) and 36mo (95% CI 13-59), respectively (P= 0.016). OS in the 3 groups were immature but not significantly different. Second line therapy occurred in 87.5%, 92.9% and 81.8% in the V, I/I and I/V groups respectively (in those who progressed after initial therapy). Second line response rate post first line V, I/I and I/V were 11%, 0% and 0% respectively as per RECIST 1.1. 63% of patients receiving VEGF front line therapy subsequently received immune therapy. 95% of patients receiving first line immune/immune or immune/VEGF combination therapy received VEGF therapy in the second line. Only 70% of patients who progressed on second line therapy got 3rd line therapy across all arms. Conclusions: Response rates after front line immune combination therapy are modest. The sequencing of PD-1 therapy after VEGF monotherapy appears particularly relevant in outcomes. A high proportion of patients are sequencing therapy and reaching third line which may help improve outcomes.

APA, Harvard, Vancouver, ISO, and other styles

29

Hu, Bo Hua, Celia Zhang, and Mitchell D. Frye. "Immune cells and non-immune cells with immune function in mammalian cochleae." Hearing Research 362 (May 2018): 14–24. http://dx.doi.org/10.1016/j.heares.2017.12.009.

Full text

APA, Harvard, Vancouver, ISO, and other styles

30

Herich, R., and M. Levkut. "Lactic acid bacteria, probiotics and immune system." Veterinární Medicína 47, No. 6 (March 30, 2012): 169–80. http://dx.doi.org/10.17221/5821-vetmed.

Full text

Abstract:

Mucous membranes of the body are in direct contact with the outside environment and they are colonised by a large number of different bacteria. Through mucous membranes, the organism is in permanent con-tact with different antigens. Mucous surfaces are protected by many defence mechanisms that ensure a permanent and effective protection. They include the production of secretory IgA, the production of mucus, cytoprotective peptides, defensins etc. Indigenous microflora markedly affects the structure of the host mucous, its function, and the development of the whole immune system. Protective microflora prevents pathogens from adhering by competi-tion for substrates and places of adhesion, and they simultaneously produce antibacterial substances and stimulate the production of specific antibodies and mucus. The early colonisation of the gut with living micro-organisms is important for the development of the gut protection barrier. The number of immune and epithelial cells increases. Probiotic micro-organisms including lactic acid bacteria (LAB) positively influence the composition of the gut microflora; they stimulate the production of secretory IgA; they affect the targeted transportation of the luminal antigens to Peyer’s patches and they increase the production of IFN-g. LAB stimulate the activity of non-specific and specific immune cells. These properties of the LAB depend on the particular species or strain of bacteria. These singularities are probably determined by differences in the cell wall composition. LAB belong to a group of benefi-cially acting bacteria and they are able to eliminate damage to the gut microenvironment; they stimulate local and systemic immune responses and they maintain the integrity of the gut wall.

APA, Harvard, Vancouver, ISO, and other styles

31

Souza, Felipe. "Neurological Diseases Associated to Immune Checkpoint Inhibitors." Neuroscience and Neurological Surgery 8, no. 6 (April 16, 2021): 01–08. http://dx.doi.org/10.31579/2578-8868/177.

Full text

Abstract:

The treatment for cancer has been more widespread and new therapies appear as alternatives in the area to contain the advance of the tumor, having with the immune mechanisms one of the main sources of research and study for a possible advance in the treatment. Checkpoint inhibitors (ICI) are monoclonal therapy, which act by blocking the PD-1, PD-L1 and CTLA-4 molecules, responsible for immune control. However, among the effects caused by therapy, the use of medications is associated with neurological diseases reported as an adverse effect. Neurological complications can affect both the central and the peripheral nervous system, reaching a variety of regions and being related to effects in several diseases. In clinical practice, the report in question shows how the adverse effects of using these therapies work, collaborating with evidence on the use or not of it. This bibliographic review, which used the PUBMED database with the words "antibodies", "monoclonal", "immune control", "checkpoints inhibitors", brings the main neurological diseases associated with therapy, as well as the incidence, symptoms and treatment. Methodology: The present review used as a means of obtaining information the PUBMED platform, in which it was looking for articles using the words "" antibodies "," monoclonal "," immune control "," checkpoints inhibitors ", in addition to fulfilling the year criteria between 2010 and 2020. The language and countries in which the data were obtained were not selected, so information from articles published in several countries was used.

APA, Harvard, Vancouver, ISO, and other styles

32

Gupta, PD. "Age Gracefully: Keep the Immune System Healthy." Gastroenterology Pancreatology and Hepatobilary Disorders 5, no. 5 (September 10, 2021): 01–02. http://dx.doi.org/10.31579/2641-5194/046.

Full text

Abstract:

Inflammation clock or iAge clock which was developed recently that can measure inflammation products in the body of an individual and can predict immunological decline. It is also capable of predicting incurring age-associated diseases. The quantity and quantity of these inflammatory products is also related physiological age. This will be useful information in the hands of researchers who are engaged in drug development. This will also be a helpful tool in therapeutics for clinicians.

APA, Harvard, Vancouver, ISO, and other styles

33

Kim, DaeHee, and Joseph P. Erinjeri. "Postablation Immune Microenvironment: Synergy between Interventional Oncology and Immuno-oncology." Seminars in Interventional Radiology 36, no. 04 (October 2019): 334–42. http://dx.doi.org/10.1055/s-0039-1696704.

Full text

Abstract:

AbstractCurrent tumor thermal ablation techniques rely on extreme temperatures to induce irreversible cellular injury and coagulative tissue necrosis. Ablation-induced cellular injury or death releases cancer neoantigens and activates the cancer-immunity cycle, potentially generating tumor-specific immune effectors. However, multiple negative regulatory modulators exist at each step of the cycle, mitigating meaningful and therapeutic anticancer effect provided by the immune system. Recent studies have focused on the introduction and testing of adjuvant immunotherapy combined with ablation to synergistically shift the equilibrium out of inhibitory immune modulation. This article reviews the immune microenvironment in relation to image-guided ablation techniques and discusses current and upcoming novel strategies to take advantage of antitumor immunity.

APA, Harvard, Vancouver, ISO, and other styles

34

Almogi-Hazan, Osnat, and Reuven Or. "Cannabis, the Endocannabinoid System and Immunity—the Journey from the Bedside to the Bench and Back." International Journal of Molecular Sciences 21, no. 12 (June 23, 2020): 4448. http://dx.doi.org/10.3390/ijms21124448.

Full text

Abstract:

The Cannabis plant contains numerous components, including cannabinoids and other active molecules. The phyto-cannabinoid activity is mediated by the endocannabinoid system. Cannabinoids affect the nervous system and play significant roles in the regulation of the immune system. While Cannabis is not yet registered as a drug, the potential of cannabinoid-based medicines for the treatment of various conditions has led many countries to authorize their clinical use. However, the data from basic and medical research dedicated to medical Cannabis is currently limited. A variety of pathological conditions involve dysregulation of the immune system. For example, in cancer, immune surveillance and cancer immuno-editing result in immune tolerance. On the other hand, in autoimmune diseases increased immune activity causes tissue damage. Immuno-modulating therapies can regulate the immune system and therefore the immune-regulatory properties of cannabinoids, suggest their use in the therapy of immune related disorders. In this contemporary review, we discuss the roles of the endocannabinoid system in immunity and explore the emerging data about the effects of cannabinoids on the immune response in different pathologies. In addition, we discuss the complexities of using cannabinoid-based treatments in each of these conditions.

APA, Harvard, Vancouver, ISO, and other styles

35

Amanam, Idoroenyi, Rohan Gupta, Vinod Pullarkat, and Matthew Mei. "Immune thrombocytopenia after immune checkpoint inhibitor therapy." British Journal of Haematology 193, no. 3 (March 13, 2021): 677–81. http://dx.doi.org/10.1111/bjh.17387.

Full text

APA, Harvard, Vancouver, ISO, and other styles

36

Ooi, B. S., and D. J. Cohen. "Host immune deficiency in immune complex nephritis." Journal of the American Society of Nephrology 6, no. 5 (November 1995): 1342–46. http://dx.doi.org/10.1681/asn.v651342.

Full text

Abstract:

Evidence is reviewed that indicates that an immune deficiency state may underlie patients with immune complex nephritis. Studies in several laboratories provide data that show defective immune function in patients with nephritis at the following loci: defective immunoglobulin production, impaired monocyte Fc and C3b receptor function, diminished complement biosynthesis, and decreased mesangial cell colony-stimulating factor-1 biosynthesis. Aberrant monocyte function may be an important common denominator. The validation of this hypothesis has important implications for therapeutic strategies.

APA, Harvard, Vancouver, ISO, and other styles

37

Hausmann, Martin, and Gerhard Rogler. "Immune-non Immune Networks in Intestinal Inflammation." Current Drug Targets 9, no. 5 (May 1, 2008): 388–94. http://dx.doi.org/10.2174/138945008784221152.

Full text

APA, Harvard, Vancouver, ISO, and other styles

38

Chen, Guopu, Hui Zhang, Huan Wang, and Fengyuan Wang. "Immune tolerance induced by immune-homeostatic particles." Engineered Regeneration 2 (2021): 133–36. http://dx.doi.org/10.1016/j.engreg.2021.09.007.

Full text

APA, Harvard, Vancouver, ISO, and other styles

39

Chen, Guopu, Hui Zhang, Huan Wang, and Fengyuan Wang. "Immune tolerance induced by immune-homeostatic particles." Engineered Regeneration 2 (2021): 133–36. http://dx.doi.org/10.1016/j.engreg.2021.09.007.

Full text

APA, Harvard, Vancouver, ISO, and other styles

40

Ullrich, Stephen E. "Immune modulation by phototherapy: why immune suppression?" Expert Review of Dermatology 3, no. 1 (February 2008): 7–9. http://dx.doi.org/10.1586/17469872.3.1.7.

Full text

APA, Harvard, Vancouver, ISO, and other styles

41

Powell, Don W. "Immune/Non-Immune Cell Interactions: Intestinal Myofibroblasts." Inflammatory Bowel Diseases 3, no. 2 (1997): 143–44. http://dx.doi.org/10.1097/00054725-199706000-00009.

Full text

APA, Harvard, Vancouver, ISO, and other styles

42

Berntorp, E., and I. M. Nilsson. "Immune Tolerance and the Immune Modulation Protocol." Vox Sanguinis 70, no. 1 (1996): 36–41. http://dx.doi.org/10.1159/000462140.

Full text

APA, Harvard, Vancouver, ISO, and other styles

43

Zhang, Jiakui, Qiuye Zhang, Yingwei Li, Lili Tao, Fan Wu, Yuanyuan Shen, Qianshan Tao, et al. "Immune dysregulation in primary immune thrombocytopenia patients." Hematology 23, no. 8 (February 6, 2018): 510–16. http://dx.doi.org/10.1080/10245332.2018.1435021.

Full text

APA, Harvard, Vancouver, ISO, and other styles

44

Wang, Jie, Hong-sheng Lin, Meng-yu Liu, and Yong Li. "Immune reconstitution of acquired immune deficiency syndrome." Chinese Journal of Integrative Medicine 16, no. 6 (November 26, 2010): 557–64. http://dx.doi.org/10.1007/s11655-010-0573-2.

Full text

APA, Harvard, Vancouver, ISO, and other styles

45

Blume, Joshua, Steven D. Douglas, and Dwight L. Evans. "Immune suppression and immune activation in depression." Brain, Behavior, and Immunity 25, no. 2 (February 2011): 221–29. http://dx.doi.org/10.1016/j.bbi.2010.10.008.

Full text

APA, Harvard, Vancouver, ISO, and other styles

46

Kuwana, M. "Dysregulated negative immune regulators in immune thrombocytopenia." ISBT Science Series 9, no. 1 (July 2014): 217–22. http://dx.doi.org/10.1111/voxs.12065.

Full text

APA, Harvard, Vancouver, ISO, and other styles

47

Oates, John A., Alastair J. J. Wood, and John M. Dwyer. "Manipulating the Immune System with Immune Globulin." New England Journal of Medicine 326, no. 2 (January 9, 1992): 107–16. http://dx.doi.org/10.1056/nejm199201093260206.

Full text

APA, Harvard, Vancouver, ISO, and other styles

48

Berntorp, E., and I. M. Nilsson. "Immune Tolerance and the Immune Modulation Protocol." Vox Sanguinis 70 (February 1996): 36–41. http://dx.doi.org/10.1111/j.1423-0410.1996.tb01347.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

49

McKenzie, Christopher G. J., Li Guo, John Freedman, and John W. Semple. "Cellular immune dysfunction in immune thrombocytopenia (ITP)." British Journal of Haematology 163, no. 1 (August 12, 2013): 10–23. http://dx.doi.org/10.1111/bjh.12480.

Full text

APA, Harvard, Vancouver, ISO, and other styles

50

Iyer, Priyanka C., Maria E. Cabanillas, Steven G. Waguespack, Mimi I. Hu, Sonali Thosani, Victor R. Lavis, Naifa L. Busaidy, Sumit K. Subudhi, Adi Diab, and Ramona Dadu. "Immune-Related Thyroiditis with Immune Checkpoint Inhibitors." Thyroid 28, no. 10 (October 2018): 1243–51. http://dx.doi.org/10.1089/thy.2018.0116.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!